Vancouver biotech Zymeworks closes US$929M Theravance deal
Theravance deal diversifies Zymeworks’ portfolio beyond cancer-focused businessCategories
Recent Posts

Transportation Safety Board calls for better wheel checks after train derailment

Update: Woodfibre LNG expresses disappointment after Squamish council turns down $142 million offer

7 in 10 B.C. newcomers who don't own homes intend to buy one: survey

NDP's David Eby says some Conservatives want B.C. to be 'American protectorate'

Investor advocacy group says existing prediction market restrictions should remain

Quebec City man accused of planning a chemical attack to benefit ISIS group

Vietnam's leader To Lam upgrades Canada to a strategic partner

Businesses shouldn't bet on return to normal Canada-U.S. relations: former ambassador

Unionized workers at Metro produce centre in Laval, Que., ratify new deal
GET MORE INFORMATION
